- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04199689
Эффективность против оральной персистирующей инфекции, иммуногенность и безопасность 9-валентной вакцины против папилломавируса человека (9vHPV) у мужчин в возрасте 20–45 лет (V503-049)
Фаза 3, международное, многоцентровое, рандомизированное, двойное слепое, плацебо-контролируемое клиническое исследование для изучения эффективности, иммуногенности и безопасности вакцины 9vHPV, мультивалентной вакцины с частицами, подобными вирусу L1, в профилактике персистентной персистенции Заражение ВПЧ типов 16, 18, 31, 33, 45, 52 или 58 у взрослых мужчин в возрасте от 20 до 45 лет
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9vHPV vaccine in men 20 to 45 years of age. The primary hypothesis tested after the primary database lock is that administration of a 3-dose regimen of 9vHPV vaccine will reduce the incidence of human papillomavirus (HPV) 16/18/31/33/45/52/58-related oral persistent infection (6 months or longer) compared with placebo.
There will also be an Extension Study to offer an opportunity to complete the 3 dose regimen of 9vHPV vaccine for participants who received placebo in the Base Study, or received less than 3 doses of 9vHPV vaccine in the Base Study.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
Antwerpen
-
Wilrijk, Antwerpen, Бельгия, 2610
- University of Antwerp ( Site 0352)
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Бельгия, 3000
- Universitair Ziekenhuis Gasthuisberg ( Site 0353)
-
Tienen, Vlaams-Brabant, Бельгия, 3300
- Femicare VZW ( Site 0350)
-
-
-
-
-
São Paulo, Бразилия, 05402-000
- Centro de Pesquisa Clinica II - ICHC - FMUSP ( Site 0102)
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Бразилия, 40415-006
- Hospital Santo Antonio - Obras Sociais Irma Dulce ( Site 0101)
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Бразилия, 59025-050
- CPCLIN ( Site 0100)
-
-
-
-
-
Berlin, Германия, 10787
- Epimed GmbH ( Site 0450)
-
Berlin, Германия, 10787
- Klinische Forschung Berlin ( Site 0454)
-
Hamburg, Германия, 20246
- Universitatsklinikum Hamburg-Eppendorf ( Site 0451)
-
-
Hesse
-
Frankfurt am Main, Hesse, Германия, 60596
- Infektiologikum Frankfurt-Sachsenhausen ( Site 0456)
-
-
-
-
-
Haifa, Израиль, 3525408
- Rambam Medical Center ( Site 0601)
-
Jerusalem, Израиль, 9112001
- Hadassah Medical Center. Ein Kerem ( Site 0600)
-
-
Central District
-
Kfar Saba, Central District, Израиль, 4428164
- Meir Medical Center ( Site 0602)
-
Tel Aviv, Central District, Израиль, 6789140
- Maccabi Health Services Medical Center ( Site 0604)
-
-
-
-
Barcelona
-
Badalona, Barcelona, Испания, 08916
- Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 0755)
-
Centelles, Barcelona, Испания, 08540
- CAP Centelles ( Site 0751)
-
L'Hospitalet de Llobregat, Barcelona, Испания, 08090
- ICO L Hospitalet ( Site 0754)
-
-
-
-
-
Bari, Италия, 70124
- Azienda Ospedaliera Policlinico di Bari ( Site 0550)
-
Catania, Италия, 95123
- AOU Policlinico Vittorio Emanuele ( Site 0552)
-
Roma, Италия, 00161
- Universita di Roma "La Sapienza" ( Site 0553)
-
-
Roma
-
Rome, Roma, Италия, 00144
- Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 0551)
-
-
Veneto
-
Padova, Veneto, Италия, 35128
- Azienda Ospedaliera - Universita di Padova ( Site 0555)
-
-
-
-
Antioquia
-
Medellín, Antioquia, Колумбия, 050021
- Fundacion Centro de Investigacion Clinica CIC ( Site 0153)
-
-
Atlántico
-
Barranquilla, Atlántico, Колумбия, 080020
- Clinica de la Costa Ltda. ( Site 0152)
-
-
Cundinamarca
-
Chía, Cundinamarca, Колумбия, 250001
- Centro de Atención e Investigación Médica SAS - CAIMED CHIA ( Site 0156)
-
-
-
-
-
Chihuahua City, Мексика, 31000
- Icaro Investigaciones en Medicina S.A. de C.V. ( Site 0200)
-
Veracruz, Мексика, 91910
- ARKE Estudios Clinicos S.A de C.V ( Site 0211)
-
-
Mexico City
-
Mexico City, Mexico City, Мексика, 06700
- Arke Estudios Clinicos S.A. de C.V. ( Site 0203)
-
-
Morelos
-
Cuernavaca, Morelos, Мексика, 62100
- Instituto Nacional de Salud Publica ( Site 0202)
-
-
-
-
-
Lima, Перу, 07006
- Policlinico Universidad Nacional Mayor de San Marcos ( Site 0257)
-
Lima, Перу, 15046
- Investigaciones Medicas en Salud - INMENSA ( Site 0255)
-
Lima, Перу, 15423
- Instituto de Investigacion Nutricional - Anexo Huascar ( Site 0251)
-
Lima, Перу, LIMA 01
- Asociacion Via Libre ( Site 0250)
-
-
Loreto
-
Iquitos, Loreto, Перу, 16000
- Asociacion Civil Selva Amazonica ( Site 0252)
-
-
-
-
California
-
Northridge, California, Соединенные Штаты, 91325
- Valley Clinical Trials Inc. ( Site 0002)
-
Rialto, California, Соединенные Штаты, 92377
- Inland Empire Clinical Trials, LLC ( Site 0025)
-
Simi Valley, California, Соединенные Штаты, 93065
- Alta California Medical Group ( Site 0031)
-
Spring Valley, California, Соединенные Штаты, 91978
- Encompass Clinical Research ( Site 0028)
-
Walnut Creek, California, Соединенные Штаты, 94598
- Diablo Clinical Research, Inc ( Site 0042)
-
-
Florida
-
Coral Gables, Florida, Соединенные Штаты, 33134
- Clinical Research of South Florida ( Site 0036)
-
Miami, Florida, Соединенные Штаты, 33142
- Acevedo Clinical Research Associates ( Site 0001)
-
Tampa, Florida, Соединенные Штаты, 33617
- Moffitt Cancer Center ( Site 0017)
-
-
Georgia
-
Augusta, Georgia, Соединенные Штаты, 30912
- Augusta University ( Site 0010)
-
-
Idaho
-
Meridian, Idaho, Соединенные Штаты, 83646
- Solaris Clinical Research, LLC ( Site 0003)
-
-
Kansas
-
Topeka, Kansas, Соединенные Штаты, 66606
- Cotton-O'Neil Clinical Research Center ( Site 0044)
-
Wichita, Kansas, Соединенные Штаты, 67207
- Heartland Research Associates, LLC ( Site 0034)
-
-
Kentucky
-
Bardstown, Kentucky, Соединенные Штаты, 40004
- Kentucky Pediatric/Adult Research Inc ( Site 0011)
-
-
Missouri
-
Hazelwood, Missouri, Соединенные Штаты, 63042
- Healthcare Research Network LLC ( Site 0035)
-
-
Nevada
-
Las Vegas, Nevada, Соединенные Штаты, 89119
- Alliance for Multispecialty Reseach, LLC ( Site 0021)
-
-
New York
-
Cortland, New York, Соединенные Штаты, 13045
- Certified Research Associates ( Site 0041)
-
New York, New York, Соединенные Штаты, 10011
- Laser Surgery Care ( Site 0018)
-
New York, New York, Соединенные Штаты, 10065
- Weill Cornell Medicine ( Site 0046)
-
Rochester, New York, Соединенные Штаты, 14609
- Rochester Clinical Research, Inc. ( Site 0008)
-
-
North Carolina
-
Salisbury, North Carolina, Соединенные Штаты, 28144
- PMG Research of Salisbury ( Site 0009)
-
-
Ohio
-
Cleveland, Ohio, Соединенные Штаты, 44122
- Rapid Medical Research, Inc. ( Site 0037)
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15236
- Preferred Primary Care Physicians ( Site 0032)
-
-
South Carolina
-
North Charleston, South Carolina, Соединенные Штаты, 29405
- Coastal Carolina Research Center ( Site 0043)
-
-
Tennessee
-
Kingsport, Tennessee, Соединенные Штаты, 37660
- Holston Medical Group ( Site 0030)
-
-
Texas
-
Galveston, Texas, Соединенные Штаты, 77555-1115
- University of Texas Medical Branch at Galveston ( Site 0038)
-
Houston, Texas, Соединенные Штаты, 77081
- Texas Center For Drug Development ( Site 0013)
-
Victoria, Texas, Соединенные Штаты, 77901
- Crossroads Clinical Research LLC ( Site 0027)
-
-
Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84121
- J Lewis Research Inc/Foothill Family Clinic South ( Site 0006)
-
South Jordan, Utah, Соединенные Штаты, 84095
- J Lewis Research Inc/Jordan River Family Medicine ( Site 0023)
-
-
Virginia
-
Charlottesville, Virginia, Соединенные Штаты, 22911
- Charlottesville Medical Research Center, LLC ( Site 0007)
-
Newport News, Virginia, Соединенные Штаты, 23606
- Health Research of Hampton Roads, Inc. ( Site 0015)
-
Richmond, Virginia, Соединенные Штаты, 23226
- Clinical Research Partners, LLC. ( Site 0004)
-
-
-
-
-
Chiang Mai, Таиланд, 50200
- Research Institute for Health Sciences ( Site 1053)
-
-
Bangkok
-
Bangkok, Bangkok, Таиланд, 10400
- Armed Forces Research Institute of Medical Sciences ( Site 1051)
-
Bangkok, Bangkok, Таиланд, 10400
- Vaccine Trial Center Faculty of Tropical Medicine ( Site 1052)
-
Bangkok, Bangkok, Таиланд, 10700
- Faculty of Medicine Siriraj Hospital ( Site 1050)
-
-
-
-
-
Kaohsiung City, Тайвань, 833
- Chang Gung Medical Foundation. Kaohsiung Branch ( Site 1003)
-
Tainan, Тайвань, 70403
- National Cheng Kung University Hospital ( Site 1002)
-
Taipei, Тайвань, 100
- National Taiwan University Hospital ( Site 1000)
-
Taoyuan, Тайвань, 333
- Chang Gung Medical Foundation.Linkou Branch ( Site 1001)
-
-
-
-
Cote-d Or
-
Dijon, Cote-d Or, Франция, 21079
- CHU Dijon Bourgogne - Hopital F. Mitterrand ( Site 0223)
-
-
Herault
-
Montpellier, Herault, Франция, 34295
- Hopital Saint Eloi ( Site 0504)
-
-
Ille-et-Vilaine
-
Rennes, Ille-et-Vilaine, Франция, 35033
- C.H.R.U. de Rennes. Hopital de Pontchaillou ( Site 0507)
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Франция, 44093
- CHU Nantes - Hopital Hotel Dieu ( Site 0510)
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Франция, 75014
- Hopital Cochin ( Site 0506)
-
-
-
-
-
Olomouc, Чехия, 772 00
- G-CENTRUM Olomouc s.r.o. ( Site 0400)
-
Prague, Чехия, 120 00
- MediStar s.r.o. ( Site 0403)
-
Prague, Чехия, 150 06
- FN Motol ( Site 0402)
-
-
Brno-mesto
-
Brno, Brno-mesto, Чехия, 602 00
- Centrum ambulantni gynekologie a primarni pece ( Site 0401)
-
-
-
-
-
Seoul, Южная Корея, 03312
- The Catholic University of Korea Eunpyeong St Mary s Hospital ( Site 0954)
-
Seoul, Южная Корея, 03722
- Severance Hospital ( Site 0953)
-
Seoul, Южная Корея, 07441
- Hallym University Kangnam Sacred Heart Hospital ( Site 0951)
-
Seoul, Южная Корея, 08308
- Korea University Guro Hospital ( Site 0950)
-
-
Kyonggi-do
-
Ansan-si, Kyonggi-do, Южная Корея, 15355
- Korea University Ansan Hospital ( Site 0952)
-
-
-
-
-
Fukuoka, Япония, 810-0001
- Sagiyama Urology Clinic ( Site 1116)
-
Fukuoka, Япония, 812-0025
- Souseikai PS Clinic ( Site 1103)
-
Kumamoto, Япония, 861-4157
- Souseikai Nishikumamoto Hospital ( Site 1104)
-
Osaka, Япония, 532-0003
- Medical Corporation Heishinkai OPHAC Hospital ( Site 1105)
-
Osaka, Япония, 542-0076
- Nomura Clinic Namba ( Site 1114)
-
Osaka, Япония, 542-0086
- Medical Corporation Seiwakai Hayakawa Clinic ( Site 1113)
-
Tokyo, Япония, 101-0041
- Doujin Memorial Medical Foundation, Meiwa Hospital ( Site 1111)
-
Tokyo, Япония, 107-0052
- Taisei Clinic ( Site 1109)
-
Tokyo, Япония, 144-0051
- Medical Corporation Mori to Umi Tokyo Tokyo Kamata Hospital ( Site 1112)
-
Tokyo, Япония, 158-0097
- Naoko Dermatology Clinic ( Site 1107)
-
Tokyo, Япония, 160-0017
- Medical Corporation Shinanokai Shinanozaka Clinic ( Site 1106)
-
Tokyo, Япония, 160-0022
- Medical Corporation Iseikai My City Clinic ( Site 1108)
-
Tokyo, Япония, 171-0014
- Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic ( Site 1102)
-
Tokyo, Япония, 175-0092
- Kusunoki Clinic ( Site 1110)
-
-
Tokyo
-
Hachiōji, Tokyo, Япония, 192-0071
- P-One Clinic, Keikokai Medical Corp. ( Site 1101)
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
Base Study:
- Is healthy and is judged to be in good physical health based on medical history and physical examination
- Has provided written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research
- Agrees to provide study personnel with a primary telephone number as well as an alternate means of contact, if available (such as an alternate telephone number or email) for follow-up purposes
- Can read, understand, and complete the electronic vaccination report card (eVRC)
- Has had at least 1 lifetime sexual partner
Extension Study:
- Participants may continue in the Extension Study if Inclusion Criteria #1 and #4 are still met, and the participants was in either the placebo group in the Base Study or the vaccine group in the Base Study but did not complete the vaccination series
- Provides documented consent for the Extension Study
Exclusion Criteria:
Base Study:
- Has a history of HPV-related anal lesion (anal intraepithelial neoplasia or anal cancer) or HPV related head and neck cancer
- Has a history of or clinical evidence at the Day 1 external genital examination of HPV-related external lesion
- Has clinical evidence at the Day 1 external genital examination of gross genital lesion suggesting sexually transmitted disease
- Has a fever (defined as oral temperature ≥100.0°F or ≥37.8°C) within a 24-hour period prior to Day 1 visit
- Has a history of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention
- Is allergic to any vaccine component, including aluminum, yeast, or BENZONASE®
- Has known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
- Is currently immunocompromised or has been diagnosed as having congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition
- Has a history of splenectomy
- Has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate by judgment of investigator
- Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence at the discretion of the investigator. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems because of alcohol use
- Has received within 12 months prior to enrollment, is receiving, or plans to receive during the study, the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (ARAVA®), TNF-α antagonists, monoclonal antibody therapies (including rituximab [RITUXAN®]), intravenous immunoglobulin (IVIG), anti-lymphocyte sera, or other therapy known to interfere with the immune response. Regarding systemic corticosteroids, a participant will be excluded if he is currently receiving steroid therapy, has recently received such therapy, or has received 2 or more courses of high-dose corticosteroids (≥20 mg/day of prednisone [or equivalent] orally or parenterally) lasting at least 1 week in duration in the year prior. Participants using inhaled, nasal, or topical steroids are considered eligible for the study
- Has received within the 3 months prior to vaccination, is receiving, or plans to receive during the study, any immune globulin product (including RhoGAM™) or blood-derived product other than IVIG
- Has received inactivated or recombinant vaccines within 14 days prior to vaccination or receipt of live vaccines within 21 days prior to vaccination
- Is concurrently enrolled in other clinical studies of investigational agents
- Has previously received a marketed HPV vaccine, or has participated in a clinical trial for any HPV vaccine (receiving either active agent or placebo)
- Has engaged in sexual activity 48 hours prior to vaccination. Sexual activity is defined as: penile penetrative vaginal intercourse with female partner; penile penetrative or receptive anal intercourse with male or female partner; or oral sex involving any contact between participant's mouth with a female partner's vagina, genital or anal area or male partner's penis or genital or anal area. This also includes any contact between participant's partner's mouth with participant's penis, genital or anal area
- Is unlikely to adhere to the study procedures, keep appointments, or is planning to permanently relocate from the area prior to the completion of the study or to leave for an extended period when study visits would need to be scheduled
- Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study
Extension Study:
- Participants must be excluded from the Extension Study if Base Study Exclusion Criteria #4, 5, 6, 7, 10, 16, or 18 are met
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Профилактика
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Тройной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: 9vHPV vaccine
Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6 |
9vHPV is an aluminum-adjuvanted recombinant protein vaccine prepared from the highly purified virus-like particles of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 given as a 0.5 mL intramuscular injection.
Другие имена:
|
|
Плацебо Компаратор: Placebo
Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6 |
0.9% sodium chloride given as a 0.5-mL intramuscular injection |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Incidence of HPV 16/18/31/33/45/52/58-related 6-month Persistent Oral Infection
Временное ограничение: Up to Month 90
|
A 6-month persistent infection is defined to have occurred if a participant, after completion of the Month 7 visit, is positive for the same HPV type by the HPV polymerase chain reaction (PCR) assay to at least 1 common gene in Oral Rinse and Gargle (ORG) samples obtained at 2 or more consecutive visits at 6 months (+/-1 month visit window) apart. |
Up to Month 90
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Incidence of HPV 6/11-related 6-month Persistent Oral Infection
Временное ограничение: Up to Month 90
|
A 6-month persistent infection is defined to have occurred if a participant, after completion of the Month 7 visit, is positive for the same HPV type by the HPV PCR assay to at least 1 common gene in ORG samples obtained at 2 or more consecutive visits at 6 months (+/-1 month visit window) apart. |
Up to Month 90
|
|
Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 Antibodies
Временное ограничение: 1 month postdose 3 (Month 7)
|
Serum antibodies to HPV types are measured with competitive Luminex immunoassay (cLIA). Geometric mean titers of antibodies to HPV types will be calculated by exponentiating the mean estimates of natural logarithm of the anti-HPV titers. |
1 month postdose 3 (Month 7)
|
|
Percentage of Participants who Seroconvert to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
Временное ограничение: 1 month postdose 3 (Month 7)
|
Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive by 4 weeks postdose 3. A participant with anti-HPV cLIA titer at or above the serostatus cutoff of the cLIA for a given HPV type is considered seropositive for that HPV type. |
1 month postdose 3 (Month 7)
|
|
Percentage of Participants with at Least 1 Solicited Injection-site Adverse Event (AE)
Временное ограничение: Up to 5 days after any vaccination
|
An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Solicited injection-site AEs such as redness/erythema, swelling, and tenderness/pain at the injection site will be recorded. |
Up to 5 days after any vaccination
|
|
Percentage of Participants with Elevated Temperature (Fever)
Временное ограничение: Up to 5 days after any vaccination
|
Participants are asked to record oral body temperatures. The percentage of participants with elevated temperature (≥37.8°C or 100.0°F) will be assessed. |
Up to 5 days after any vaccination
|
|
Percentage of Participants Who Report at Least 1 Systemic AE
Временное ограничение: Up to 15 days after any vaccination
|
An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Systemic AEs are those not categorized as injection-site AEs. |
Up to 15 days after any vaccination
|
|
Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)
Временное ограничение: Up to 15 days after any vaccination
|
A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is another important medical event deemed such by medical or scientific judgment. |
Up to 15 days after any vaccination
|
|
Percentage of Participants who Experience at Least 1 Serious Vaccine-Related AE
Временное ограничение: Up to Month 90
|
A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is another important medical event deemed such by medical or scientific judgment. An SAE that is considered by an investigator (a qualified physician) to be vaccine-related will be reported during entire study period. |
Up to Month 90
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Medical Director, Merck Sharp & Dohme LLC
Публикации и полезные ссылки
Общие публикации
- Giuliano AR. Initiation of three complementary international studies investigating prevalence of oral HPV infection, burden of HPV-related head and neck disease, and efficacy of 9-valent HPV vaccination against oral HPV persistent infection. Contemp Clin Trials. 2022 Apr;115:106629. doi: 10.1016/j.cct.2021.106629. Epub 2021 Nov 24. No abstract available.
- Morais E, Kothari S, Roberts C, Yen G, Chen YT, Lynam M, Pedros M, Mirghani H, Alemany L, Pavon MA, Waterboer T, Mehanna H, Giuliano AR. Oral human papillomavirus (HPV) and associated factors among healthy populations: The design of the PROGRESS (PRevalence of Oral hpv infection, a Global aSSessment) study. Contemp Clin Trials. 2022 Apr;115:106630. doi: 10.1016/j.cct.2021.106630. Epub 2021 Nov 25.
- Giuliano AR, Wilkin T, Bautista OM, Cheon K, Connor L, Dubey S; Thomas Group; Luxembourg A, Rawat S, Shaw A, Velicer C, Vendetti N, Tu Y. Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men. Contemp Clin Trials. 2022 Apr;115:106592. doi: 10.1016/j.cct.2021.106592. Epub 2021 Oct 19.
- Bergman H, Henschke N, Arevalo-Rodriguez I, Buckley BS, Crosbie EJ, Davies JC, Dwan K, Golder SP, Loke YK, Probyn K, Petkovic J, Villanueva G, Morrison J. Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. Cochrane Database Syst Rev. 2025 Nov 24;11(11):CD015364. doi: 10.1002/14651858.CD015364.pub2.
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Генитальные заболевания
- Патологические процессы
- Атрибуты болезни
- Инфекции
- Вирусные заболевания
- Передающиеся заболевания
- Заболевания, передающиеся половым путем, вирусные
- Заболевания, передающиеся половым путем
- ДНК-вирусные инфекции
- Опухолевые вирусные инфекции
- Патологические состояния, признаки и симптомы
- Папилломавирусные инфекции
- Терапия
- Маршруты Управления лекарств
- Лекарственная терапия
- Неорганические химические вещества
- Хлорные соединения
- Соединения натрия
- Хлориды
- Соляная кислота
- Инъекции
- Хлорид натрия
Другие идентификационные номера исследования
- V503-049
- V503-049 (Другой идентификатор: MSD)
- 205346 (Идентификатор реестра: JAPIC-CTI)
- U1111-1275-8682 (Идентификатор реестра: UTN)
- 2019 (Грант/контракт NIH США)
- 2022-501974-21-00 (Идентификатор реестра: EU CT)
- 2019-003236-23 (Номер EudraCT)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .